Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADIANT: Neoadjuvant Durvalumab + Radiation in Bladder Cancer
NCT04543110Phase 2Unknown
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Jan 2021
- Primary completion
- Oct 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in bladder carcinoma, sponsored by Ottawa Hospital Research Institute. Primary endpoint: Pathological Complete Response Rate up to 2 years. Status: unknown.
02
Drugs
durvalumab
03
Conditions
bladder carcinoma
Beyond the preview
Go deeper on NCT04543110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04543110.